Special offersSpecial offers
AntiviralsAntivirals
Famvir Generic Famvir
Famciclovir 250mg 		BUY NOWBUY NOW €2.36 Per pill
Lamprene Generic Lamprene
Clofazimine 50mg 		BUY NOWBUY NOW €2.16 Per pill
Rebetol Generic Rebetol
Ribavirin 200mg 		BUY NOWBUY NOW €5.89 Per pill
Relenza Generic Relenza
Zanamivir 5mg 		BUY NOWBUY NOW €117.87 Per item
Symmetrel Generic Symmetrel
Amantadine 100mg 		BUY NOWBUY NOW €0.87 Per pill
Tamiflu Generic Tamiflu
Oseltamivir 75mg 		BUY NOWBUY NOW €6.29 Per pill
Valtrex Generic Valtrex
Valacyclovir 0.5/1g 		BUY NOWBUY NOW €4.10 Per pill
Zovirax Generic Zovirax
Acyclovir 200/400/800mg 		BUY NOWBUY NOW €0.50 Per pill
Search for pillsSearch for pills

TestimonialsTestimonials
Just wanted to write and say that I'm VERY satisfied with my purchase. I was skeptical at first, the price seemed too good and the shipping process too convoluted. But I sucked it up and took the plunge, ordered 90 of the lil blue guys and sat back to wait for packages that might never come. Happily I was SO wrong! 9 days after my order was placed I received my first batch of 30+4, and just today (another week later) I received the remaining 60. The quality of the product is outstanding. If you\'re sitting there, wondering whether or not you should go ahead and make a purchase here, quit wondering! The best prices, excellent service, and a top-notch product are all present here. Go for it!
Read more »Read more »
NewsNews
    Broad-Spectrum Antivirals: The Future of HIV Treatment? - TheBody.com
    Broad-Spectrum Antivirals: The Future of HIV Treatment?TheBody
    The Global Antivirals Market Expected To Reach $30 Billion By 2017 - OfficialWire (press release)
    The Global Antivirals Market Expected To Reach $30 Billion By 2017OfficialWire (press release)by Press Office In 2010, the global antivirals market was estimated to be worth $22
    deadly pandemic a matter of when, not if - Sydney Morning Herald
    deadly pandemic a matter of when, not ifSydney Morning HeraldThe drugs that would help are the antivirals, such as Relenza and Tamiflu
    Experts Discuss DAAs for Difficult-To-Treat Hep C Patients - Infectious Disease Special Edition
    Infectious Disease Special EditionExperts Discuss DAAs for Difficult-To-Treat Hep C PatientsInfectious Disease Special Editionby Christina Frangou San Francisco—For several months, it has been one of the most pressing questions among clinicians who treat patients with hepatitis C: How well do the two FDA-approved direct-acting antivirals (DAAs) perform in the patients who
    New Antivirals Show Poor Safety in HCV With Cirrhosis - Medscape
    New Antivirals Show Poor Safety in HCV With CirrhosisMedscapeMay 2, 2012 (Barcelona, Spain) — Two relatively new direct-acting antiviral drugs have poor safety profiles in patients with hepatitis C virus (HCV) and cirrhosis, including a high rate of serious adverse events leading to study discontinuation
Live support Online Chat


Our billing is certified by
Secure shopping certificates






AR AU CA CZ DK EU FR GR IT NZ NO PL PT ES FI SE NL UK US HU TR